Technologies for Size-Based Analysis of Circulating Cell-Free DNA: Limitations and Clinical Implementation.

Abstract excerpt

Prostate cancer is the second most common malignancy in men worldwide, and incidence is likely to rise in the next decade. The current screening options have limitations and have been shown to result in over-treatment of clinically insignificant disease. New biomarkers and technologies to detect them are therefore needed to better diagnose and stratify patients in primary care. Circulating cell-free DNA (ccfDNA)...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Biomarkers
• Share to Cell-Free Nucleic Acids
• Share to Mutation